#1 Clinical Trials Search in Europe

Erlotinib

This article explores the use of erlotinib (Tarceva) in various clinical trials for different types of cancer. Erlotinib is a targeted therapy drug that works by blocking a protein called epidermal growth factor receptor (EGFR), which is found on the surface of many cancer cells. The trials aim to evaluate the efficacy, safety, and potential benefits of erlotinib in treating cancers such as non-small cell lung cancer, breast cancer, and other types of tumors.

Table of Contents

What is Erlotinib?

Erlotinib, also known by its brand names Tarceva or OSI-774, is a medication primarily used in the treatment of certain types of cancer[1]. It belongs to a class of drugs called tyrosine kinase inhibitors, which are designed to target specific proteins involved in cancer growth[2].

How Erlotinib Works

Erlotinib works by blocking the activity of a protein called epidermal growth factor receptor (EGFR) found on the surface of many tumor cells. This protein controls tumor growth and survival, and by inhibiting its activity, erlotinib may stop tumors from growing[3]. This targeted approach allows erlotinib to focus on cancer cells while potentially causing fewer side effects compared to traditional chemotherapy.

Conditions Treated with Erlotinib

Erlotinib is primarily used to treat several types of cancer, including:

  • Non-Small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer. Erlotinib is particularly effective in patients with NSCLC that has specific mutations in the EGFR gene[4].
  • Pancreatic Cancer: Erlotinib is approved for use in combination with other drugs for advanced pancreatic cancer[3].
  • Bronchioloalveolar Carcinoma (BAC): This is a subtype of NSCLC. Some clinical trials have specifically studied erlotinib’s effectiveness in treating BAC[5].

In some cases, erlotinib is being studied for its potential use in other types of cancer, such as certain forms of breast cancer[3].

How Erlotinib is Administered

Erlotinib is typically taken as an oral medication in the form of tablets. The usual dose is 150 mg taken once daily, but this can vary depending on the specific condition being treated and individual patient factors[6]. It’s important to take erlotinib as prescribed by your doctor. Some key points to remember:

  • Take erlotinib on an empty stomach, either 1 hour before or 2 hours after eating[1].
  • Try to take it at the same time each day[1].
  • Do not change your dose or stop taking erlotinib without first consulting your doctor.

Erlotinib in Clinical Trials

Numerous clinical trials have been conducted to study the effectiveness of erlotinib in various scenarios. Some notable areas of research include:

  • First-line treatment: Studies have looked at using erlotinib as an initial treatment for patients with advanced NSCLC, particularly those with EGFR mutations[2].
  • Combination therapy: Researchers have investigated combining erlotinib with other cancer treatments to potentially improve outcomes[6].
  • Re-challenge treatment: Some studies have explored using erlotinib again in patients who previously benefited from it but developed resistance[4].
  • Elderly patients: Clinical trials have specifically looked at the effectiveness and safety of erlotinib in older patients with NSCLC[1].

Potential Side Effects

Like all medications, erlotinib can cause side effects. Some of the most common side effects include:

  • Skin rash
  • Diarrhea
  • Loss of appetite
  • Fatigue
  • Shortness of breath

It’s important to discuss any side effects you experience with your healthcare provider. They can provide guidance on managing side effects and may adjust your treatment if necessary[1].

Erlotinib in Combination Therapy

In some cases, erlotinib may be used in combination with other cancer treatments to potentially enhance its effectiveness. Some combinations that have been studied include:

  • Erlotinib with chemotherapy: Some trials have looked at combining erlotinib with traditional chemotherapy drugs[7].
  • Erlotinib with bevacizumab: This combination has been studied in patients with certain types of lung cancer[8].
  • Erlotinib with other targeted therapies: Researchers have explored combining erlotinib with other drugs that target specific cancer pathways[9].

The effectiveness and safety of these combinations can vary, and they may not be appropriate for all patients. Your oncologist will determine the best treatment approach based on your specific situation.

Aspect Details
Drug Name Erlotinib (Tarceva, OSI-774)
Mechanism of Action EGFR tyrosine kinase inhibitor
Cancer Types Studied Non-small cell lung cancer, breast cancer, bronchioloalveolar cell lung cancer, skin cancer, ependymoma
Administration Oral, daily dosing (typically 150 mg/day or based on body surface area)
Treatment Duration Varies by trial; ranges from 28 days to 1 year or longer
Primary Outcomes Tumor response, progression-free survival, safety profile
Common Side Effects Skin rash, diarrhea, loss of appetite, fatigue
Special Populations Elderly patients, previously treated patients, specific genetic profiles
Combination Therapies Some trials explore erlotinib in combination with surgery and/or radiation

FAQ

  • What is erlotinib (Tarceva)? Erlotinib, also known by its brand name Tarceva, is a targeted therapy drug that works by blocking the epidermal growth factor receptor (EGFR) protein found on many cancer cells. It is designed to slow or stop tumor growth.
  • What types of cancer are being studied with erlotinib in clinical trials? Clinical trials are exploring the use of erlotinib in various cancers, including non-small cell lung cancer (NSCLC), breast cancer, bronchioloalveolar cell lung cancer, and ependymoma. Some trials are also investigating its potential in treating familial adenomatous polyposis and aggressive squamous cell cancers of the skin.
  • How is erlotinib administered in these clinical trials? In most trials, erlotinib is administered orally, typically as a daily dose. The dosage may vary depending on the specific trial and cancer type being studied. Some trials use a standard dose of 150 mg per day, while others may adjust the dose based on the patient's body surface area or other factors.
  • What are some potential side effects of erlotinib? Common side effects of erlotinib may include skin rash, diarrhea, loss of appetite, and fatigue. The clinical trials closely monitor patients for adverse events and may adjust dosages or discontinue treatment if severe side effects occur.
  • How long do patients typically receive erlotinib in these clinical trials? The duration of erlotinib treatment in clinical trials varies. Some studies administer the drug for a fixed period, such as 28 days or up to 6 months, while others continue treatment as long as the patient is benefiting and not experiencing severe side effects. In some cases, treatment may last up to a year or more.

Ongoing Clinical Trials on Erlotinib

  • Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Molecularly Tailored Therapy Versus Standard Care in Patients With Advanced Pancreatic Cancer Using Olaparib, Erlotinib, Crizotinib, Trametinib, Pemigatinib, Selpercatinib, Axitinib, Vismodegib, Pembrolizumab, Larotrectinib, Dabrafenib, Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan, Gemcitabine, Paclitaxel Albumin-Bound, and Calcium Folinate

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Denmark

  • Study of Ramucirumab and Erlotinib for Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Dabrafenib and Drug Combination for Patients with Metastatic Non-Clear Cell Kidney Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of Erlotinib and LY2875358 for Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Mutations After Initial Erlotinib Treatment

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

  • Study on Bevacizumab and Erlotinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Italy

  • Study of Abemaciclib and Erlotinib for Patients with Stage IV Non-Small Cell Lung Cancer with KRAS Mutation After Platinum-Based Chemotherapy

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Erlotinib: A targeted therapy drug that inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, used in the treatment of various cancers.
  • Tarceva: The brand name for erlotinib, a targeted cancer therapy drug.
  • EGFR (Epidermal Growth Factor Receptor): A protein found on the surface of some cells that plays a role in cell growth and division. Some cancer cells have too much EGFR, which can cause them to grow more quickly.
  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that is the most common form of the disease, accounting for about 80-85% of all lung cancers.
  • Bronchioloalveolar Cell Lung Cancer: A rare subtype of non-small cell lung cancer that develops in the small air sacs of the lungs.
  • Familial Adenomatous Polyposis (FAP): An inherited disorder characterized by the growth of numerous polyps in the large intestine and rectum, which can lead to colorectal cancer if left untreated.
  • Ependymoma: A type of tumor that can form in the brain or spinal cord, arising from ependymal cells in the central nervous system.
  • Tyrosine Kinase Inhibitor: A type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in cell signaling, growth, and division.
  • Progression-Free Survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • RECIST (Response Evaluation Criteria In Solid Tumors): A standard way to measure how well a cancer patient responds to treatment, based on whether tumors shrink, stay the same, or get bigger.

References

  1. https://clinicaltrials.gov/study/NCT00200395
  2. https://clinicaltrials.gov/study/NCT00615758
  3. https://clinicaltrials.gov/study/NCT00739063
  4. https://clinicaltrials.gov/study/NCT01189435
  5. https://clinicaltrials.gov/study/NCT00590902
  6. https://clinicaltrials.gov/study/NCT00840125
  7. https://clinicaltrials.gov/study/NCT02178397
  8. https://clinicaltrials.gov/study/NCT00436332
  9. https://clinicaltrials.gov/study/NCT01545947